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Cellular pharmacodynamic effects of
Pycnogenol® in patients with severe
osteoarthritis: a randomized controlled pilot
study
Steffen Jessberger1, Petra Högger1*, Franca Genest2, Donald M. Salter3 and Lothar Seefried2
Abstract
Background: The standardized maritime pine bark extract (Pycnogenol®) has previously shown symptom alleviating
effects in patients suffering from moderate forms of knee osteoarthritis (OA). The cellular mechanisms for this positive
impact are so far unknown. The purpose of the present randomized pilot controlled study was to span the knowledge
gap between the reported clinical effects of Pycnogenol® and its in vivo mechanism of action in OA patients.
Methods: Thirty three patients with severe OA scheduled for a knee arthroplasty either received 100 mg of
Pycnogenol® twice daily or no treatment (control group) three weeks before surgery. Cartilage, synovial fluid and
serum samples were collected during surgical intervention. Relative gene expression of cartilage homeostasis markers
were analyzed in the patients’ chondrocytes. Inflammatory and cartilage metabolism mediators were investigated in
serum and synovial fluid samples.
Results: The oral intake of Pycnogenol® downregulated the gene expression of various cartilage degradation markers
in the patients’ chondrocytes, the decrease of MMP3, MMP13 and the pro-inflammatory cytokine IL1B were statistically
significant (p ≤ 0.05). Additionally, protein concentrations of ADAMTS-5 in serum were reduced significantly (p≤ 0.05)
after three weeks intake of the pine bark extract.
Conclusions: This is the first report about positive cellular effects of a dietary supplement on key catabolic and
inflammatory markers in patients with severe OA. The results provide a rational basis for understanding previously
reported clinical effects of Pycnogenol® on symptom scores of patients suffering from OA.
Trial registration: ISRCTN10754119. Retrospectively registered 08/10/2015.
Keywords: Pycnogenol, Maritime pine bark extract, Osteoarthritis, Clinical study, ADAMTS, Cartilage, Synovial fluid,
Serum, qPCR
Background
Osteoarthritis (OA) is a highly prevalent degenerative joint
disease causing pain, joint stiffness and disability [1]. It has
been estimated that by the year 2030 more than 20% of the
adults will suffer from OA in the western countries [2]
which leads to increasing global health costs. Current
pharmacologic treatment only allows management of
symptoms without effects on disease progression and may
be associated with potential adverse side effects [3]. The
perceived burden of suffering often prompts patients to
seek therapeutic alternatives, e.g. plant-derived remedies.
Dietary factors or supplements have been discussed as op-
tions in the management or prevention of OA [4] and their
potential as chondroprotectives has been investigated [5].
A dietary supplement which has shown clinical effects in
patients with mild forms of knee OA (Kellgren-Lawrence
grade I and II) is the standardized maritime pine bark ex-
tract Pycnogenol® [6–8]. In three double-blind randomized
placebo-controlled studies with 37–159 patients receiving
100 mg [7] or 150 mg [6, 8] Pycnogenol® per day over three
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months, statistically significant reductions of the composite
Western Ontario and McMaster Universities (WOMAC)
score summarizing pain, joint stiffness and daily activities
were observed. Additionally, a decrease in the concomitant
use of analgesic drugs was reported. The cellular mecha-
nisms responsible for the positive effects of Pycnogenol® on
the clinical symptoms are unknown.
The pine bark extract is a complex mixture of poly-
phenolic compounds [9]. A pharmacokinetic study with
volunteers ingesting Pycnogenol® revealed that catechin,
caffeic acid, ferulic acid, and taxifolin were detectable in a
nanomolar range in plasma [10]. Moreover, a catechin
metabolite (M1) produced by human intestinal bacteria
was found in the plasma samples. Subsequent investiga-
tions showed that M1 exerted various anti-inflammatory
effects in vitro such as the inhibition of the activity of the
matrix metalloproteinases MMP-1, −2 and −9, decrease of
the release of MMP-9 from human monocytes or inhibition
of the expression of the inducible NO synthase (iNOS) in
RAW 264.7 macrophages [11, 12]. In other in vitro experi-
ments using the whole extract a decrease of IL1B mRNA
synthesis in RAW 264.7 cells was reported [13] as well as
inhibitory effects on the expression of COX-2, IL-8 and
iNOS in human chondrocytes and fibroblasts [14].
However, since not all components of the extract are bio-
available and other bioactive molecules such as M1 are gen-
erated in vivo, it is not clear whether experiments using the
whole extract would be indicative for cellular effects that
actually occur in vivo.
The results of in vitro and ex vivo approaches with the
maritime pine bark extract are interesting in the context of
the pathology of OA which is characterized by loss of ar-
ticular cartilage and remodeling processes, pain and func-
tional impairment [15, 16]. Destructive effects are related to
an increase of cartilage catabolism while anabolic processes
are suppressed. Various biomarkers are upregulated in OA
patients and can be detected in serum or plasma samples,
synovial fluid or urine. The pro-inflammatory cytokine IL-
1β actives various signal transduction pathways e.g. via NF-
κB that result in upregulation of pro-inflammatory media-
tors and cartilage degrading proteolytic enzymes such as
MMP-1, MMP-3 and MMP-13 [15]. MMPs degrade
collagen and aggrecan, the major proteoglycan in human
articular cartilage. Aggrecan is also targeted by another
class of metalloproteinases, the aggrecanases-1 and -2, also
known as “A Disintegrin and Metalloproteinase with
Thrombospondin Motifs” (ADAMTS4, −5) [16, 17]. The
role of different ADAMTS is not definitely resolved so far.
In mice, ADAMTS-5 seems to be the most important en-
zyme degrading aggrecan molecule [18]. ADAMTS5
knockout mice are protected from cartilage loss, whereas
ADAMTS4-KO mice are not [19]. In humans, both en-
zymes play a role in the pathophysiology of OA [17, 20].
Cartilage degradation by MMPs, ADAMTS and also
cathepsins generates various decomposition products such
as type II collagen fragments, CTX-II (carboxy-terminal
telepeptides of type II collagen) and Helix-II (type II
collagen helical peptide) [21]. Aggrecan depletion is
indicated by sulfated glycosaminglycans (sGAG) [17].
So far research insights regarding the cellular effects of
plant-based extracts or single constituents on relevant OA
biomarkers have been gained from in vitro cell culture
studies and experiments with animals receiving peroral or
intra-articular treatment [5, 22]. To the best of our know-
ledge there has been no approach reported which involves
OA patients taking a plant extract and determines effects
on biomarkers simultaneously in the participants’ articular
cartilage, synovial fluid and serum. The purpose of the
present pilot study was to span the knowledge gap
between the reported clinical efficacy of Pycnogenol® and
its in vivo mechanism of action in OA patients.
Methods
Patients and study design
The present study was a randomized controlled clinical trial
involving patients suffering from severe osteoarthritis (OA)
of the knee according to the WOMAC score who were
scheduled for an elective arthroplasty (Kellgren-Lawrence
grade III-IV). Patients were not eligible if they regularly
took NSAIDs or glucocorticoids p.o. within the past four
weeks, if they currently received a therapy with anti-
coagulants or if they were tested positive for HIV, HCV or
HCB or if they had a previous or current infection of the
affected knee joint. As rescue medication acetaminophen
(paracetamol), tramadol or a combination of tilidine and
naloxone was allowed. The study protocol was reviewed
and approved (reference number 248/11) by the local
Ethics Committee of the Medical Faculty of the University
Würzburg. The procedures followed were in accordance
with the ethical standards of the Ethics Committee and
with the Helsinki Declaration of 1975, as revised in 2000.
Since the study primarily focused on pharmacokinetic/bioa-
nalytical aspects (see [23]) an early registration was
overlooked and the study was registered retroactively. The
authors confirm that all their ongoing and related trials
performed for this drug/intervention are registered.
A total of 33 OA patients were recruited for the study
and gave written informed consent. The number of partici-
pants was chosen based on an earlier pharmacokinetic
study with healthy volunteers [10]. With respect to cellular
pharmacodynamic effects the present study was of explora-
tory nature due to lack of reference data. The insights
generated can be used as rational basis for future sample
size calculations in similar study settings. Patients were
randomized into two groups using a computer-generated
randomization list which was not accessible to the physi-
cians and nurses who were involved in the patient care and
management. Study participants were either assigned to the
Jessberger et al. BMC Complementary and Alternative Medicine  (2017) 17:537 Page 2 of 12
treatment group (n = 16) receiving 200 mg Pycnogenol®
(Horphag Research Ltd., Geneva, Switzerland) per day
(twice daily two capsules with each 50 mg) over three
weeks prior to the planned surgery or to the control group
(n = 17) who received no Pycnogenol®. All patients were
asked to refrain from polyphenol-rich food/beverages. Nu-
tritional check-lists were provided for specifying food/bev-
erages to avoid and for recording ingested items within the
last two days before blood sampling. Adherence to the
study medication was estimated based on counting the
number of returned Pycnogenol® capsules. Patients who
ingested more than 80% of study medication were consid-
ered to be adherent.
Blood samples were collected (BD Vacutainer® SST II
Advance; 13 mm× 100 mm; Becton Dickinson GmbH,
Heidelberg, Germany) before oral intake of Pycnogenol®
(V1, basal value); during the intake, approximately 1–2 days
before the surgery (V2); and during or shortly before knee
surgery (V3), about 12 h after the last dose of Pycnogenol®.
On the day of the surgery residual knee cartilage and syn-
ovial fluid were also collected. The knee fragments were
stored in DMEM for 0.5 to 1 h until further processing.
Serum and synovial fluid samples were shock-frozen and
stored at −80 °C. The outcome measures were the expres-
sion / concentrations of various inflammatory and degrada-
tions markers in chondrocytes, synovial fluid and serum.
All medical procedures including enrollment of partici-
pants, surgery, patient care and sample collection took place
at the orthopedic center (Orthopädie und Orthopädische
Klinik König-Ludwig-Haus, Universität Würzburg) between
September 2012 and September 2014. The generation of
the random allocation sequence, assignment of participants
to the intervention or control group and analysis of all pa-
tient samples took place at the Institut für Pharmazie und
Lebensmittelchemie.
Chemicals and reagents
Buffers and cell culture media were all obtained from Sigma
Aldrich (Taufkirchen, Germany). Fungizone®, Type-II-
Collagenase and recombinant human interleukin-1β were
purchased from Life Technologies (Darmstadt, Germany).
Fetal bovine serum (FBS), Trypan blue solution 0.5% [m/v]
and L-glutamine (200 mM) were obtained from Biochrom
AG (Berlin, Germany). All disposable items used in cell cul-
ture or sample handling were purchased from Sarstedt AG
(Nümbrecht, Germany) or Greiner-bio one (Frickenhausen,
Germany).
Treatment of cartilage
The complete residual articular cartilage was removed
from the patients’ samples to analyze the average expres-
sion of marker genes in the chondrocytes. The cartilage
was cut into 1–2 mm2 fragments and placed in an anti-
microbial solution containing 5 mL Fungizone® and 5 mL
L-glutamine (200 mM) in 100 mL Dulbecco’s phosphate
buffered saline (PBS) for 30 min at room temperature.
The digestion procedure has been described elsewhere
[14]. Briefly, the pieces were washed three times with PBS
and digested with trypsin 0.25% / EDTA 0.02% for 30 min
at 37 °C and 5% CO2. After repeating the washing step the
cartilage fragments were incubated with a solution of 0.3%
(m/v) type-II collagenase in IMDM over night at 37 °C
and 5% CO2. Then the cell suspension was filtered
through an autoclaved metal wire (VWR, Darmstadt) to
remove remaining large cartilage fragments. After centri-
fuging the suspension at 1560 g for 10 min at room
temperature the cell pellet was suspended and washed in
10 mL of PBS. This washing step was repeated twice. The
cell pellet was resuspended in 7.5 mL IMDM and filtered
through a 70 μm cell sieve. The cell yield was determined
using a Neubauer counting chamber after 1:1-dilution of
the suspension with trypan blue solution 0.5% (m/v). Cell
aliquots of approximately 1 × 106 cells were shock-frozen
in liquid nitrogen and stored at −80 °C. Only cell samples
showing >95% viability were used for further experiments.
RNA extraction and cDNA synthesis
Total RNA from human primary chondrocytes was ex-
tracted using a high pure RNA isolation kit (Roche Diag-
nostics, Mannheim, Germany). Concentration and purity of
the resulting RNA was analyzed with an Infinite® 200 PRO
NanoQuant (TECAN Ltd. Group, Männedorf, Switzerland)
using the i-control™ Microplate Plate Reader software, ver-
sion 1.10 (TECAN Ltd. Group). Only samples with a ratio
of A260nm/A280nm between 1.9 and 2.1 were accepted. For
first strand complementary DNA synthesis, 250 ng, 500 ng
or 1 μg of total RNA, dependent on the yield, were tran-
scribed into cDNA in a two-step process with a Transcrip-
tor First Strand cDNA synthesis kit (Roche Diagnostics)
according to the manufacturer’s instructions and using
oligo dT-primers.
Quantitative real-time polymerase chain reaction (qPCR)
Complementary DNAs were amplified under following
conditions: 95 °C for 3 min, 40 cycles of 95 °C for 10 s and
60 °C for 30 s using the iTaq™Universal SYBR®Green-Mas-
terMix (BioRad Laboratories GmbH, München, Germany)
and a Stratagene Mx3005P qPCR system (Agilent Tech-
nologies, Waldbronn, Germany) with MxPro-Software,
version 4.10 (Agilent Technologies). Specific primers were
designed with the PrimerBLAST™ software for each target
and housekeeping gene and were obtained from Eurofins
MWG GmbH (Ebersberg, Germany) (Table 1). The qPCR
mix contained 10 μL SYBR®Green Master Mix, 2 μL of a
1:10-dilution of cDNA and varying amounts of primers
and water up to a final volume of 20 μL. Optimal primer
concentrations were determined using a primer matrix
(Table 2). During housekeeping gene validation the gene
Jessberger et al. BMC Complementary and Alternative Medicine  (2017) 17:537 Page 3 of 12
expression of β-actin (ACTB) and hypoxanthine phos-
phoribosyl transferase 1 (HPRT-1) were identified as the
most stable reference genes under the chosen conditions
(n = 5; Fig. 1). Mean efficiencies of amplification processes
ranged from 92% to 99% (Table 2). Amplification efficiencies
of all genes and Ct-values of target and reference genes were
included in the calculations using the REST® 2009-software
[24]. A melting curve analysis was performed after each run
to control the specificity of the amplification process.
Determination of marker concentrations in serum and
synovial fluid
Human MMP-1 and MMP-13 ELISA kits were purchased
from RayBiotech® (Norcross, GA, USA). Human ADAMTS-4
ELISA kit was obtained from Novateinbio (Woburn, MA,
USA) and human ADAMTS-5 ELISA kit was purchased
from Cusabio (Wuhan, China). Human MMP-3 CytoSet™
and Antibody Pair Buffer Kit were produced by Invitrogen
Corporation (Frederick, USA). The synovial fluid samples
were centrifuged at 1000 g for 10 min using the Megafuge 1.0
R Thermo Scientific (Waltham, MA, USA). The assays were
then performed according to the manufacturers’ protocols.
Dimethyl-methylene blue (DMMB) assay
Shark chondroitin sulfate, used as a standard, DL-
dithiothreitol (DTT), papain from papaya latex, iodacetic
acid and DMMB were obtained from Sigma Aldrich. A
calibration curve in a range of 0.25–5 μg chondroitin sul-
fate in water was obtained (UV mini-1240; Shimadzu,
Duisburg, Germany) for calculating the concentrations of
sulfated glucosamine glycans (sGAG) in synovial fluid
samples of patients according to Farndale et al. [25].
Briefly, synovial fluid samples were diluted 1:10 with a so-
lution of 1 mM Na2H2EDTA, 2 mM DL-DTT and 300 μg/
mL papain in 20 mM sodium phosphate buffer (pH = 6.8)
to a final volume of 1 mL. The mixture was incubated for
1 h at 60 °C and 300 rpm in a thermomix (Eppendorf,
Hamburg, Germany). The reaction was stopped with
1 mL 20 mM iodacetic acid and diluted with 3 mL of
50 mM TRIS/HCl buffer (pH = 8.0). 500 μL of this incuba-
tion mix were added to 2 mL of a dimethylenblue solution
and the absorption was measured at λ = 525 nm.
Statistical methods
Relative gene expressions and statistical analysis of gene
expression differences among the groups were calculated
using the REST2009® software [24]. Housekeeping genes
were evaluated with the BestKeeper® software [26]. This
software uses the standard deviation as measure for gene
expression stability with a cut-off of +/− 1 Cp value. All
other mathematical operations were performed using
the GraphPad® Prism software, version 6.0 (GraphPad
Software, Inc., La Jolla, CA, USA). Intergroup differences
were calculated with the Student’s t-test, correlations
Table 1 Specific primers used in qPCR
Gene Type Size [bp] Sequence [5'→ 3']
GAPDH forward 20 CGC TCT CTG CTC CTC CTG TT
GAPDH reverse 20 CCA TGG TGT CTG AGC GAT GT
ACTB forward 18 TGA GCG CGG CTA CAG CTT
ACTB reverse 22 TCC TTA ATG TCA CGC ACG ATT T
18sRNA forward 20 GCC TGC GGC TTA ATT TGA CT
18sRNA reverse 20 ACC AGA CAA ATC GCT CCA CC
HPRT-1 forward 22 AGC CAG ACT TTG TTG GAT TTG A
HPRT-1 reverse 21 ACT GGC GAT GTC AAT AGG ACT
B2M forward 25 AAG ATA GTT AAG TGG GAT
CGA GAC A
B2M reverse 23 AAT TCA TCC AAT CCA AAT GCG GC
SDHA forward 22 AGA CCT AAA GCA CCT GAA GAC G
SDHA reverse 24 CTC ATC AAT CCG ACC TTG TAG TC
MMP1 forward 20 TGG ACC TGG AGG AAA TCT TG
MMP1 reverse 20 GGT ACA TCA AAG CCC CGA TA
MMP3 forward 24 AGG CAA GAC AGC AAG GCA TAG AGA
MMP3 reverse 24 ACG CAC AGC AAC AGT AGG ATT GGA
MMP13 forward 22 TGG AAT TAA GGA GCA TGG CGA C
MMP13 reverse 20 ACC TAA GGA GTG GCC GAA CT
IL1B forward 24 AAT CTC CGA CCA CCA CTA CAG CAA
IL1B reverse 24 AAG GGA AAG AAG GTG CTC AGG TCA
ADAMTS5 forward 24 ACA AGA GCC TGG AAG TGA GCA AGA
ADAMTS5 reverse 24 TGA TGC CCA CAT AAA TCC TCC CGA
CTSK forward 20 TTC CCG CAG TAA TGA CAC CC
CTSK reverse 20 GGA ACC ACA CTG ACC CTG AT
Table 2 Optimal primer concentrations and amplification
efficiencies of each target gene
Gene Concentration
forward primer [μM]
Concentration
reverse primer [μM]
Amplification
efficiency [%]
GAPDH 0.15 0.15 ̶
ACTB 0.15 0.15 92.97
18sRNA 0.15 0.15 –
HPRT-1 0.15 0.15 96.93
SDHA 0.15 0.15 93.40
B2M 0.375 0.375 ̶
MMP1 0.75 0.75 96.77
MMP3 0.50 0.50 99.27
MMP13 0.75 0.75 95.27
IL1B 0.50 0.50 91.97
ADAMTS5 0.75 0.75 96.97
CTSK 0.25 0.25 99.87
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were analyzed using the Pearson’s correlation test. Statis-
tical significance was defined as p-values ≤0.05.
Results
Patients and protocol adherence
A total number of 33 patients were enrolled into the study
and randomized to receive either Pycnogenol® (n = 16) or
no treatment (n = 17). One patient of the control group
decided against the scheduled knee replacement surgery
and was excluded. During the surgical procedure blood,
synovial fluid and cartilage samples were failed to collect
for one patient each of the control and Pycnogenol® group.
These patients were excluded from the analysis (Fig. 2).
Thus, 30 patients were evaluated, 15 in the treatment group
(9 females, 6 males) and 15 in the control group (11 fe-
males, 4 males; Table 3). There was no statistically signifi-
cant difference between the groups in any of the basic
demographic characteristics (Student’s T-test, p > 0.05).
Analysis of the nutrition protocols revealed that the dietary
advice was not followed well and violations were admitted
before collecting 42% of the blood samples. In contrast, the
adherence to the study medication was excellent based on
pill count-back of the returned medication containers. All
but one study participant (#130, Pycnogenol® group; 76%)
fulfilled the adherence criteria. Without this patient, the
average adherence was 99.4% (range 96–100%). No
treatment-associated adverse effects were reported except
for one patient of the Pycnogenol® group who experienced
flatulence.
Influence of Pycnogenol® on gene expression in patients’
chondrocytes
All cDNA samples investigated for relative expression of
target genes were examined regarding the reliability of
the housekeepers using the BestKeeper® software [26].
Hypoxanthine phosphoribosyltransferase 1 (HPRT-1) and
beta actin (ACTB) were confirmed as reliable housekeep-
ing genes with standard deviations of the expression below
+/− 1 Cp value (Table 4; Fig. 1). Using two reference
genes complies with the latest MIQE guideline for
qPCR analysis [27] . Further calculations were done
without patient #119 as a statistically confirmed out-
lier regarding MMP-3 expression and patient #130
who showed less than 80% adherence to the study
medication (Table 4).
There was a clear tendency towards downregulation of the
gene expression of the matrix metalloproteinases MMP1,
MMP3 and MMP13 in the Pycnogenol® group, although the
effect was not always statistically significant due to the high
variability and the limited patient number (Table 4; Fig. 3).
MMP1 was downregulated to a ratio of 0.234 [0.005;
10.058]. The relative gene expression of MMP3 was de-
creased to 0.442 [0.087; 1.977] and to 0.367 [0.026; 3.552]
(p = 0.02) when excluding patient #119 (control group) as an
outlier regarding MMP3 expression. The additional exclu-
sion of the non-adherent patient #130 made the
downregulation of MMP3 even clearer (0.315 [0.023;
3.001] (p = 0.01)). MMP13 was downregulated by Pyc-
nogenol® to a ratio of 0.265 [0.018; 3.460]. Exclusion
of the non-adherent patient #130 resulted in a statis-
tically significant difference between the study groups
(0.292 [0.003; 8.698], p = 0.05).
The relative gene expression of IL1B was downregu-
lated to a ratio of 0.376 [0.059; 2.423]. Excluding patient
#130 due to non-adherence the tendency to down-
regulation was statistically significant (p < 0.05). Analysis
of ADAMTS5 gene expression (1.030 [0.305; 3.793]) did
not reveal any change after intake of Pycnogenol®.
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Fig. 1 Housekeeping gene validation data from five cartilage samples obtained from patients suffering from severe knee osteoarthritis. The genes HPRT-1
and SDHA were identified as the most stable ones using the BestKeeper™-software. ACTB was preferred over B2M due to its frequent use in literature
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Inflammatory and cartilage metabolism markers in
synovial fluid
The synovial fluid sample volumes of three patients of the
Pycnogenol® group (#108, #120 and #121) and one of the
control group (#106) were not sufficient to determine all bio-
markers of interest. Additionally, depending on the target,
the concentrations in some samples were below the detection
limit of the ELISA kits so that the results frequently included
less than 15 patients per study group (Table 5).
Concentrations of matrix-degrading enzymes of the
MMP family were not clearly reduced in the Pycnogenol®
group while both ADAMTS-4 and ADAMTS-5 proteins
were found at higher concentration in the intervention
Fig. 2 CONSORT 2010 Flow diagram of the study (see http://www.consort-statement.org/)
Table 3 Basic demographic characteristics of the patients
participating in the study
Parameter Pycnogenol® group Control group Total
Number of patients 15 15 30
Age [years] 63.3 ± 7.6 65.3 ± 8.8 64.3 ± 8.2
Body height [m] 1.69 ± 0.10 1.69 ± 0.11 1.69 ± 0.10
Body weight [kg] 90.22 ± 15.95 79.90 ± 24.12 87.33 ± 15.66
BMI [kg/m2] 30.87 ± 4.72 28.98 ± 4.14 30.74 ± 5.29
Percentage of
women [%]
60 73.3 66.7
Table 4 Relative gene expressions of cartilage homeostasis
markers in chondrocytes of patients treated with Pycnogenol®
compared to controls
Target gene Exclusion Relative expression [95% CI] P-value
MMP1 none 0.234 [0.005; 10.058] 0.15
MMP3 none 0.442 [0.087; 1.977] 0.07*
MMP3 #119 0.367 [0.026; 3.552] 0.02**
MMP3 #130 0.394 [0.025; 13.198] 0.04**
MMP3 #119, #130 0.315 [0.023; 3.001] 0.01**
MMP13 none 0.265 [0.018; 3.460] 0.06*
MMP13 #130 0.292 [0.003; 8.698] 0.05*
IL1B none 0.376 [0.059; 2.423] 0.08*
IL1B #130 0.359 [0.013; 7.112] <0.05**
ADAMTS5 none 1.030 [0.305; 3.793] 0.94
CTSK none 0.622 [0.143; 2.991] 0.25
Further calculations were done without patients #119 as a statistically
confirmed outlier regarding MMP3 expression and #130 who showed less than
80% adherence to the study medication
*tendency to down-regulation
**statistically significant (p ≤ 0.05)
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group compared to controls (Table 5). However, none of
the differences was statistically significant (p > 0.05).
The release of sulfated glycosaminoglycans (sGAG)
into synovial fluid was lower in the group treated with
Pycnogenol® compared to untreated controls although
this effect did not reach statistical significance (Table 5).
Type II collagen fragments, CTX-II (carboxy-terminal
telepeptides of type II collagen) and Helix-II (type II
collagen helical peptide), were reduced in the Pycno-
genol® group, but the high inter-individual variability
again impeded statistical differentiation of the groups.
Alteration of cartilage metabolism markers in serum
Serum samples from each patient were obtained both
before (V1) and after (V2 and V3) intake of Pycnogenol®.
V3 samples were primarily used for analysis of Pycno-
genol® constituents and metabolites [23].
There was a significant difference in the changes of pro-
tein concentrations of ADAMTS-5 in serum from V1 to
V2 between the Pycnogenol® treated group (n = 15)
compared to the control group (n = 15) (p = 0.02; Fig. 4).
The mean decline of 31.12 ± 67.85 ng/mL ADAMTS-5 in
the Pycnogenol® group was opposed by an increase of
33.37 ± 72.82 ng/mL in the control group. After excluding
a statistically confirmed outlier in the control group (pa-
tient #132; Δc = −188 ng/mL; identified by GraphPad®
Prism Software), the difference among the groups was
even more pronounced (p = 0.001).
The analysis of MMP-13 concentrations revealed a simi-
lar trend (Fig. 5). There was a minor decrease of 2.62 ±
20.17 pg/mL MMP-13 in the Pycnogenol® group (n = 4)
compared to a slight increase of 20.87 ± 25.09 pg/mL in
control patients (n = 7). The difference between the
groups was not statistically significant (p = 0.15). The
MMP-13 serum concentrations of 19 patients were below
the lower limit of detection of the ELISA and therefore
excluded from calculations.
There were no relevant changes of the serum concen-
trations of other markers between V1 and V2 in any of
the two groups (data not shown).
Fig. 3 Relative gene expression of several marker genes of cartilage homeostasis. The relative gene expression of targets was calculated by
dividing the expression of the gene of interest by the geometric mean of the expression of the reference genes. All target genes showed a
tendency to downregulation in the Pycnogenol® group (n = 14) in relation to the control group (n = 14). The relative gene expression of the
particular targets in the control group is referred to as “1”. Calculations and box-and-whisker-plots were made with the REST2009® software.
The dashed lines in the boxes symbolize the median of the relative expressions
Table 5 Concentrations of various inflammatory and cartilage metabolism protein markers in the synovial fluid of patients treated
with Pycnogenol® compared to controls
Target Pycnogenol® group (n) Control group (n) P-value
MMP-1 11.61 ± 8.61 ng/mL (9) 14.04 ± 6.93 ng/mL (12) 0.47
MMP-3 7.06 ± 2.46 ng/mL (12) 7.10 ± 2.72 ng/mL (13) 0.96
MMP-13 0.23 ± 0.13 ng/mL (13) 0.27 ± 0.18 ng/mL (14) 0.51
CTX-II 236.76 ± 168.08 pg/mL (12) 428.90 ± 511.83 pg/mL (14) 0.23
Helix-II 0.90 ± 0.68 nmol/L (12) 1.23 ± 1.19 nmol/L (15) 0.57
sGAG 356.89 ± 61.89 μg/mL (12) 390.32 ± 53.81 μg/mL (15) 0.19
ADAMTS-4 32.50 ± 33.26 ng/mL (9) 22.55 ± 19.69 ng/mL (12) 0.42
ADAMTS-5 12.58 ± 10.83 ng/mL (12) 7.08 ± 4.28 ng/mL (15) 0.12
Jessberger et al. BMC Complementary and Alternative Medicine  (2017) 17:537 Page 7 of 12
Correlation analysis of biomarkers
The ΔCt values of the MMP3 expression in relation to
the housekeeping gene HPRT-1 statistically significantly
correlated with the concentration of CTX-II in synovial
fluid (SF) (r = −0.548, p = 0.01; n = 23). Thus, higher
gene expression levels of MMP3 in cartilage resulted in
higher CTX-II levels in synovial fluid (Fig. 6). A similar
correlation was seen for the expression of MMP1 and
CTX-II. The correlations were statistically significant
using ACTB or HPRT-1 as reference genes (p = 0.049
and p = 0.042, n = 23).
Effect parameters were also correlated with concentra-
tions of the constituents of Pycnogenol® and its metabolite
M1 in serum, synovial fluid and in blood cells [23]. Higher
concentrations of ferulic acid in synovial fluid significantly
correlated with lower MMP-3 protein levels in this speci-
men (r = −0.761, p = 0.007; n = 11; Fig. 7a). In contrast, a
significant direct correlation was found between caffeic
acid and MMP-13 concentrations in serum of the study
participants (r = 0.789, p = 0.02; n = 8; Fig. 7b). Weak, but
statistically significant inverse correlations were found for
concentrations of M1 and ADAMTS-5 in serum of the
OA patients (r = −0.395, p = 0.016; n = 23; Fig. 8a) and be-
tween M1 concentrations in blood cells and ADAMTS-4
levels in serum (r = −0.445, p = 0.033; n = 23; Fig. 8b).
Discussion
This is the first report of a randomized controlled clinical
study on the cellular effects of the maritime pine bark extract
Pycnogenol® on various catabolic and inflammatory markers
in patients with severe osteoarthritis (OA) undergoing a
medically indicated knee replacement surgery. Patients with
end-stage OA were chosen since this was an ethical option
to simultaneously obtain cartilage samples and synovial fluid
along with blood samples. The recruited participants were
considered as representative OA patients with a mean age of
64.3 ± 8.2 years and an elevated BMI of 30.74 ± 5.29 kg/m2
[28]. Above the age of 60 years approximately twice as many
women (18%) suffer from OA compared to men (9.6%) [29].
This relation was also mirrored in the present study
Fig. 4 Changes of ADAMTS-5 protein concentrations in serum of the
study participants from V1 to V2 in the Pycnogenol® group (n = 15) in
relation to controls (n= 15). For each patient the ADAMTS-5 concentra-
tion after three weeks of intervention (V2) was subtracted by the con-
centration before the intervention (V1). Each dot represents a single
patient. The difference between the two groups was statistically signifi-
cant (p = 0.02), which was even more pronounced after exclusion of
one outlier in the control group (p = 0.001)
Fig. 5 Changes of MMP-13 protein concentrations in the patients’
serum samples from V1 to V2 in the Pycnogenol® group (n = 4)
compared to controls (n = 7). For each patient the MMP-13
concentration after three weeks of intervention (V2) was subtracted
by the concentration before the intervention (V1). Each dot of the
scatter plot represents a single patient. The difference between the
groups was not statistically significant which was also due to not
quantifiable levels of MMP-13 in serum samples of 19
patients (p = 0.15)
Fig. 6 Correlation between the MMP3 gene expression and the
concentration of CTX-II in synovial fluid (SF) of patients. Gene
expression is expressed as ΔCt (Ct (MMP3)-Ct (HPRT-1)). Higher
expression levels of MMP3 in cartilage resulted in higher CTX-II levels
in synovial fluid. The correlation was statistically significant (r =-0.548,
p = 0.01; n = 23). The dotted lines symbolize the 95% CI
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population which included 20 women and 10 men. After
randomization half of the recruited patients received Pycno-
genol® over three weeks prior to joint replacement surgery.
In clinical studies previously investigating the effects Pycno-
genol® on clinical symptoms the patients were treated over
three months [6–8]. All studies revealed time-dependent
effects on symptoms of OA, earliest statistically significant
differences between Pycnogenol® and placebo regarding the
overall WOMAC score were observed after six weeks [8].
Since an improvement of OA symptoms is typically a “late”
event we hypothesized that changes on a cellular level would
occur earlier. The three weeks of Pycnogenol® intake in the
present study were chosen on the basis of the time period
that the clinicians routinely scheduled between pre-
admission meetings with the patients and the surgery.
During this meeting a basic examination was performed, the
patients were supplied with the pine bark extract and pre-
intervention blood samples were collected.
Despite of the fact that three weeks of Pycnogenol® in-
take were comparatively short the expression analysis in
the articular chondrocytes revealed for all but one
parameter a downregulation of the respective gene in
the Pycnogenol® group compared to controls. The de-
creased expressions of MMP3, MMP13 and IL1B genes
were statistically significant when single factors contrib-
uting excessively to the data variability were excluded
based on statistical procedures or documented non-
adherence. A concomitant downregulation of IL1B and
the MMPs is consistent with the accepted belief that the
IL-1β protein is a strong inducer of MMP1, MMP3 and
MMP13 expression as well as inducing its own upregu-
lation [15]. In contrast, the aggrecanase ADAMTS5 was
not downregulated suggesting that its expression in the
patients’ articular chondrocytes was not or not entirely
dependent on IL-1β exposure. Indeed, there are contra-
dicting reports about the induction of ADAMTS5 by IL-
1β [15, 17]. The proteolytic cysteine protease cathepsin
K (CTSK) which contributes to collagen and aggrecan
degradation [30] was downregulated in the Pycnogenol®
group, but this effect did not reach statistical signifi-
cance. Whilst numerous in vitro or in vivo studies with
animals have demonstrated a down-regulation of MMPs
Seru
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Fig. 7 Correlations between concentrations of polyphenolic constituents
of Pycnogenol® and matrix metalloproteinases (MMPs). a. Inverse
correlation between concentrations of MMP-3 protein and ferulic acid in
the patients’ synovial fluid. This correlation was statistically significant
(r = 0.761, p = 0.007; n = 11). b. Direct relationship between MMP-13
protein concentrations and levels of caffeic acid in serum (r = 0.789,
p = 0.02; n = 8). The dotted lines symbolize the 95% CI
Fig. 8 Correlations between serum / blood cell concentrations of a
microbial metabolite (M1) of Pycnogenol® and ADAMTS protein
concentrations in serum of the patients. a. Relationship between
concentration of M1 and ADAMTS-5 levels in serum (n = 23). The inverse
correlation was weak, but statistically significant (r =−0.395; p= 0.016). b.
Relationship between concentration of M1 in blood cells and ADAMTS-4
levels in serum (n = 23). The inverse correlation was weak, but statistically
significant (r =−0.445; p= 0.033). The dotted lines symbolize the 95% CI
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and ADAMTS in chondrocytes by plant extracts or sin-
gle constituents thereof [5, 31–33], high doses are
frequently used in such settings and it is unlikely that
comparable concentrations could be achieved in human
patients. Importantly, when using complex plant extracts
it must be kept in mind that not all components are
bioavailable [34]. The present results demonstrate for
the first time that bioactive components of the dietary
supplement Pycnogenol® actually influence the gene
expression in human articular chondrocytes in vivo.
The determination of inflammatory or metabolic factors
and matrix degradation products in patients’ synovial fluid
samples revealed no statistically significant differences
between the study groups, but showed distinct tendencies.
The mean protein concentrations of both ADAMTS-4 and
ADAMTS-5 were higher in the Pycnogenol® compared to
the control group. The latter is consistent with the slightly
elevated ADAMTS5 gene transcription in the patients’
chondrocytes. However, the increased aggrecanase concen-
trations in the synovial fluid were obviously not associated
with higher proteolytic activity since the main degradation
product of the ADAMTSs, the sulfated glucosamine gly-
cans (sGAG; [17]), were even slightly lower in the
Pycnogenol® group. This might be explained by the fact that
total ADAMTS concentrations were measured and not the
aggrecanase activity. It is possible that higher ADAMTS-4
and ADAMTS-5 protein concentrations were paralleled by
an increased production of the endogenous inhibitor
TIMP-3 which inhibits both ADAMTSs at subnanomolar
concentrations [16]. Another possibility is that post-
translational processing of the ADAMTSs was not yet
completed. The ADAMTSs are synthesized as zymogens
and although they are assumed to be secreted as active
enzymes ADAMTS-4 is further processed extracellularly to
yield increased proteolytic activity [16].
In the synovial fluid MMP protein concentrations
were not clearly lower in the Pycnogenol® compared to
the control group. Again, this appears to be inconsist-
ent with the observed downregulation of MMP1,
MMP3 and MMP13 gene expression in the patients’
chondrocytes. The same reasoning as discussed with
the ADAMTS may apply to the MMPs as well. Not-
ably, mean concentrations of unspecific degradation
products, type II collagen fragments CTX-II and
Helix-II, were reduced in the Pycnogenol® group by
approximately 45% and 27%, respectively, compared to
controls. CTX-II is mainly produced by MMP-1,
MMP-3 and MMP-13 while Helix-II is generated at
high amounts by cathepsin K [21]. This suggests that
despite no obvious differences in the total MMP pro-
tein concentrations an attenuated generation of colla-
gen fragments was related to the intake of
Pycnogenol®. The reduced Helix-II concentrations in
the Pycnogenol® group were consistent with the
slightly reduced cathepsin K gene expression in the
patients’ chondrocytes.
Determination of cartilage homeostasis markers in the
serum samples revealed two remarkable results. There
was a significant (p = 0.02 and p = 0.001 after exclusion of
a confirmed outlier) decrease of ADAMTS-5 protein con-
centrations in the Pycnogenol® group compared to control
patients. This would be consistent with the anti-
inflammatory properties and clinical effects of the pine
bark extract in OA patients [7, 8, 35]. The rise of
ADAMTS-5 concentrations in the control group might be
explained by a further progression of joint disease or by
the fact that the patients were required to refrain from
anti-inflammatory analgesics. Serum levels of ADAMTS-5
have been shown to be higher in OA patients compared
to healthy controls and correlate with the stage of OA
[36]. The present study now provides the first evidence
that serum ADAMTS-5 concentrations of OA patients
decrease in response to a dietary supplement. The other
finding of note is the decrease of MMP-13 protein con-
centrations in the Pycnogenol® group compared to control
patients. The effect was not statistically significant as a
consequence of the low sample numbers. Interestingly, in
the Pycnogenol® group only four patients had measurable
MMP-13 concentrations as opposed to seven patients in
the control group. Blood levels of MMP-13 appear to be
generally low. In a biomarker study with OA patients no
MMP-13 was detected in a plasma preparation and only
some patients had measurable levels in synovial fluid [37].
The data obtained in the present study were subjected
to a correlation analysis to determine potential interrela-
tions of biomarkers and the previously analyzed poly-
phenol concentrations in the respective specimen [23].
For the first time it was shown in a human study that
higher gene expression levels of MMP3 in the patients’
cartilage significantly (p = 0.01) correlated with higher
CTX-II protein levels in synovial fluid. This is consistent
with in vitro results showing that MMP-3 efficiently
released CTX-II [21].
A significant inverse correlation (r = −0.761; p = 0.007)
was determined between MMP-3 protein levels in the pa-
tients’ synovial fluid and concentrations of ferulic acid in
the same specimen. A causal relationship is likely as feru-
lic acid downregulates MMP3 gene expression in cells
[38]. In contrast, a direct correlation between MMP-13
protein concentrations and the levels of caffeic acid in
serum (r = 0.789; p = 0.02) is less explicable or sup-
ported by similar observations. A causal relationship
might be assumed for the weak correlations of M1 and
ADAMTS-5 concentrations in serum (r = −0.395, p =
0.016) and between M1 concentrations in blood cells
and ADAMTS-4 levels in serum (r = −0.445, p = 0.033)
since M1 has been previously shown to inhibit metallo-
proteinases [11].
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The present study has some limitations. The patients in
the control group did not receive a placebo. However, the
current study did not aim at measuring clinical effects,
e.g. symptoms reported by the patients. The aim was to
investigate pharmacodynamic aspects on a cellular level as
well as pharmacokinetic aspects (see [23]). To the best of
our knowledge it is not possible to deliberately influence
the concentration or expression of inflammatory or cartil-
age degradation markers. Therefore, we think that it was
scientifically justified to have an untreated control group
in the present pilot study. Unfortunately the variability of
the obtained data was high. More pronounced group dif-
ferences might have been detected with a higher number
of patients. However, there was no pre-study data on the
effect size of the pine bark extract on inflammatory or
chondrometabolic markers in OA patients to allow for a
rational calculation of the sample size. Yet, despite of the
limited group sizes and the participants ignoring dietary
restrictions regarding polyphenols various significant ef-
fects were uncovered. Thus, even under ‘real life’ condi-
tions with occasional or regular consumption of dietary
polyphenols the intake of Pycnogenol® had additional cel-
lular effects in patients with severe OA. Clearly, the bene-
fit for the patients is not the change of inflammatory or
cartilage degradation markers, but the reduction of OA
clinical symptoms. The latter had already been shown in
clinical trials [6–8] and our study now provides a rational
basis for the reported clinical effects. A strength of the
current study was that more than one reference gene was
used for the gene expression analysis in accordance with
the MIQE guidelines [27]. Most investigations concerning
cartilage gene expressions use a single housekeeping gene,
particularly GAPDH, which showed high variance in ex-
pression in our hands consistent with observations of
others [39] and emphasizes the importance of choosing
more than one reliable reference gene. A further strength
of the present investigation is that a number of bio-
markers were analyzed on several levels, i.e. at both gene
transcription and protein level in synovial fluid and serum.
Thus, findings were substantiated by consistent observa-
tions made at different checkpoints of pathophysiologic
pathways playing a role in OA.
Conclusions
To summarize, in the present study cellular pharmaco-
dynamic properties of Pycnogenol® were investigated in
patients suffering from severe OA of the knee. For the
first time the effects of a nutraceutical were systematic-
ally researched in patients’ chondrocytes, synovial fluid
and serum in comparison with a control group. The
overall results suggest a chondroprotective potential of
the maritime pine bark extract and provide a rational
basis for understanding the reported clinical effects on
symptom scores in OA patients.
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